by Doug Park
July 23, 2009
How long should biologics enjoy protection from competition? That hotly debated question in Congress has produced a wide range of opinions, from 5, 7 to 12 years. Some Congresspeople favor a 5 year period, Howard Dean, the National Venture Capital Association, and Senator Edward Kennedy all support 12 or more years of data exclusivity for [...]
Read the full article →
by Doug Park
June 29, 2009
Centocor Ortho Biotech, a business unit of Johnson & Johnson, today won a $1.67 billion award for Abbott Labs’ infringement of its patent on Remicade. Centocor’s Remicade and Abbott’s Humira are competitors in the treatment of rheumatoid arthritis. Humira is Abbott’s best-selling pharmaceutical. Abbott’s success has relied on Humira. Humira has gained FDA approvals [...]
Read the full article →
